Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.